Insertion, AMI Cardiogenic Shock, Surgical Applications

EACTS 2022 on Demand - MCS for PCCS, Structural Heart Disease, and Advanced Cardiogenic Shock

Innovative Strategies for Superior Outcome in Cardiac Surgery Including pMCS Support in Therapy Pathway

Discover the recordings of our scientific session at EACTS 2022 about "Innovative Strategies for Superior Outcome in Cardiac Surgery Including pMCS Support in Therapy Pathway".

Chair

Prof. Dr. Roberto Lorusso, Maastricht, Netherlands
Prof. Dr. Dr. Hermann Reichenspurner, Hamburg, Germany

Speakers & Key Topics

Prevention of PCCS in high-risk Cardiac Surgery patients by elective implant of pMCS 
Prof. Dr. Assad Haneya, Kiel, Germany

Structural Heart Disease – Innovative Approaches Extending Therapy Scope by Using pMCS Support
PD Dr. Bastian Schmack, Essen, Germany

Tailored Solutions to Treat Advanced CGS Patients Combining ECMO with pMCS
Prof. Dr. Evgenij Potapov, Berlin, Germany

 

Prevention of PCCS in High-risk Cardiac Surgery Patients by Elective Implant of pMCS

Dr. Veronika Walter, a colleague of Prof. Dr. Assad Haneya, delivers his presentation on innovative strategies for superior outcome in cardiac surgery at EACTS 2022. She reviews MCS devices suitable for postcardiotomy cardiogenic shock (PCCS), focusing on ECLS (or VA ECMO), microaxial pumps (Impella® heart pumps), and a combination of both. Dr. Walter explains that patients with severely reduced left ventricular ejection fraction (LVEF) undergoing coronary artery bypass surgery (CABG) are at increased risk of PCCS and optimal timing of adequate hemodynamic support impacts outcome. Her data indicate that prophylactic LV unloading with Impella heart pumps seems to be a safe approach to prevent PCCS and to improve the outcomes in this high-risk patient population.

 

Structural Heart Disease – Innovative Approaches Extending Therapy Scope by Using pMCS Support

“Mitral valve regurgitation, especially, is a super complex pathology,” explains Dr. Bastian Schmack in this presentation from EACTS 2022. He explains the pros and cons of surgery in these patients with severe mitral valve regurgitation and poor ventricular function. While surgery can comprehensively treat the root of the underlying issue, there is high risk for peri/early postoperative low cardiac output syndrome. Dr. Schmack also discusses the role of transcatheter edge-to-edge repair (TEER) in these patients. He then describes the surgical protocol at his institution for Impella 5.5® with SmartAssist® heart pump short-term pMCS for MV surgery and severely reduced LV function as well as plans for studies to demonstrate that it is possible to transform inoperable patients into appropriate patients for high-risk structural heart surgery supported with Impella 5.5® with SmartAssist® with improved outcomes and lasting results.

 

Tailored Solutions to Treat Advanced CGS Patients Combining ECMO With pMCS

Prof. Dr. Evgenij V. Potapov discusses tailored solutions for treating advanced cardiogenic shock by combining ECLS with pMCS (ECMELLA). He explains how he uses single arterial access for ECMELLA at his institution with case video demonstrating the technique. He then describes the results seen in patients between May 2020 and September 2022 and the algorithm at his institution for temporary MCS device selection in cardiogenic shock. He concludes that axillary implanted Impella heart pumps based temporary MCS is the first choice for patients with severe cardiogenic shock and that an algorithm-based approach for escalation and de-escalation improves survival in patients with severe cardiogenic shock.

View All Posts

Sign Up for Latest Updates

NPS-3218

This information is intended for use by customers, patients, and healthcare professionals in [region] only. We recognize that the Internet is a global communications medium; however, laws, regulatory requirements, and product information for medical products can vary from country to country. The product information included here may not be appropriate for use outside [region], and the information from other sites you visit may not be appropriate for use in [region].